← Back to Analyst Consensus 
ORKA Buy
Oruka Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 18, 2026 (23 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 19, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Sep 24, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 3, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 11, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Aug 11, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Aug 11, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Aug 3, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 13, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Jul 1, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Jun 23, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 18, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 14, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Apr 29, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 28, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Apr 28, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Apr 27, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Apr 15, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Apr 13, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Apr 13, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Apr 13, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 9, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Apr 7, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Apr 6, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Apr 6, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 16, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Mar 13, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Mar 13, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 13, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| Mar 13, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Mar 13, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Jan 13, 2026 | Wedbush | maintain | Outperform → Outperform | $45 | 58% |
| Jan 12, 2026 | BTIG | maintain | Buy → Buy | $73 | 52% |
| Jan 7, 2026 | UBS | initiate | — → Buy | $50 | 54% |
| Dec 18, 2025 | Piper Sandler | initiate | — → Overweight | $75 | 54% |
| Nov 13, 2025 | Jefferies | initiate | — → Buy | $45 | 52% |
| Nov 13, 2025 | BTIG | maintain | Buy → Buy | $63 | 52% |
| Oct 27, 2025 | Guggenheim | initiate | — → Buy | $60 | 52% |
| Oct 27, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $40 | 44% |
| Oct 13, 2025 | Barclays | initiate | — → Overweight | $48 | 53% |
| Sep 29, 2025 | BTIG | reiterate | Buy → Buy | $56 | 52% |
| Sep 17, 2025 | Clear Street | maintain | Buy → Buy | $46 | 48% |
| Sep 17, 2025 | BTIG | maintain | Buy → Buy | $56 | 52% |
| Aug 18, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $45 | 44% |
| Jul 23, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $45 | 44% |
| May 15, 2025 | Wedbush | reiterate | Outperform → Outperform | $40 | 58% |
| Feb 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $45 | 44% |
| Feb 4, 2025 | Wolfe Research | initiate | — → Outperform | $20 | 53% |
| Dec 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $45 | 44% |
| Nov 25, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $45 | 44% |
Price Target Trend
Jul 2, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days